

AbbVie Clinical Pharmacology Research Unit

Information Sheet

www.abbviephase1.com

The health and safety of volunteers and employees is our priority. We have safety protocols in place to keep the unit as safe as possible.

Check In: Wednesday, October 27, 2021

Pine

Study drug and design:

AbbVie is testing an investigational drug, which is not approved by the Food and Drug Administration (FDA) or any health authority and is not currently available on the market. The objective of this study is to determine safety, tolerability, and pharmacokinetics (the amount of drug absorbed into your blood stream and how your body handles the drug) via multiple ascending dose of granule formulation whether the doses are to be given with or without food.

Minimum Subject Selection Criteria:

YOU may be eligible to take part in this clinical study if you meet the following conditions:

- ◆ Healthy men and women 18 to 65 years old.
- ◆ Females must be permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy) or postmenopausal defined as age \leq 55 years with no menses for 12 or more months without an alternative medical cause.
- ◆ Average weight for height (BMI 18 to 29.9).
- ◆ Not taking any medications or herbal remedies or supplements.
- ◆ No history of any drug sensitivity or allergy.
- ◆ No history of drug or alcohol abuse for 6 months.
- ◆ Non-user of tobacco for at least 6 months.
- ◆ No blood or blood product donation after September 02, 2021.
- ◆ No other study participation after September 28, 2021, or 5 half-lives of drug if known prior to first dose of study drug.
- ◆ No evidence of dysplasia or history of malignancy.
- ◆ Has not been previously enrolled in this study.
- ◆ No drug by injection before September 28, 2021, or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration. (30 days)
- ◆ No previous ABBV 111

Screenings at ACPRU in Grayslake

Screening dates: *(To find out if you are suitable to take part in this clinical study)*

- ◆ October 21, 22, 25 & 26, 2021
- ◆ **Additional screening dates may be available.**
- ◆ Screening appointments are between the hours of 08:00 and 11:45 and take approximately 3 hours.

Stipend:

AbbVie Clinical Pharmacology Research Unit

Information Sheet

www.abbviephase1.com

- ◆ **Screening:** \$75.00. (No compensation if urine drug/alcohol/cotinine screen is positive or if BMI is out of range.)
- ◆ **Study:** Compensation of up to \$5,250.00 may be provided if selected and you complete the study.

Study dates: *(Please note that these dates and times are subject to change)*

Must complete all periods and/or follow up visit(s).

CHECK IN: Wednesday, October 27, 2021, at scheduled check in time.

CHECK OUT: Friday, November 12, 2021, at approximately noon.

FOLLOW UP PHONE CALL: Friday, December 10, 2021, at scheduled time.

(A follow up visit may be required for safety. If this occurs, you will be notified and compensated for your visit time and travel)

(Please note that these dates and times are subject to change)

Please call our recruiting office at 1-800-827-2778 to schedule an appointment.